Valeo Pharma Inc., of Montreal, said it filed its final short form prospectus in each of the provinces and territories of Canada in connection with its sale of a minimum of 4 million units and a maximum of 16 million units at CA50 cents each for gross proceeds of between CA$2 million (US$1.53 million) and CA$8 million (US$6.13 million). 

Sonoma Pharmaceuticals Inc., of Petaluma, Calif., said it is now compliant with the minimum bid price requirement for continued listing on Nasdaq and is no longer subject to delisting at this time. To achieve compliance, the company implemented a 1-for-9 reverse stock split last month.

Horizon Therapeutics plc, of Dublin, said Horizon Pharma U.S. Inc., its wholly owned subsidiary, priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027. 

A False Claims Act suit was unsealed alleging that Johnson & Johnson fraudulently obtained a patent to block generic competition for prostate cancer drug Zytiga (abiraterone acetate), a drug that costs roughly $9,000 per month and generates about $2.4 billion in annual revenue for New Brunswick, N.J.-based J&J, according to law firm Herrera Purdy LLP. 

Schrodinger Inc., of New York, said it received a preclinical milestone payment from Sanofi SA, of Paris, in a drug discovery program advancing as part of a multiyear, multitarget collaboration.